• James L. LordanEmail author


The outcome of lung transplant recipients has progressively improved over the decades, related to improved candidate selection, the development of lung allocation policies, advances in surgical techniques, and an evolution of post-transplant care. A revision of the International Society for Heart and Lung Transplantation (ISHLT) criteria to guide referral and listing for lung transplantation is presented. Recent developments in post-transplant care are discussed, including the management of specific early and late transplant-related complications, specifically primary graft dysfunction, acute cellular and humoral rejection, infection, and chronic lung allograft dysfunction (CLAD). Effective immunosuppression is required, an awareness of drug interactions, and recognition of potential long-term adverse side effects. In the face of increasingly resistant micro-organisms, an effective anti-microbial strategy is required for optimum management. A revised classification of CLAD is discussed, including the established obstructive phenotype (Bronchiolitis Obliterans Syndrome, BOS) and a more recently described restrictive phenotype (Restrictive Allograft Syndrome, RAS), with its significant impact on long-term survival.


Lung transplantation History of transplantation Referral criteria Surgical techniques Transplant immunosuppression Transplant complications Acute rejection Infection prophylaxis Medication interactions and side effects Chronic lung allograft dysfunction 


  1. 1.
    Rutherford RM, Lordan JL, Fisher AJ, Corris PA. Historical overview of lung and heart-lung transplantation. In: Lynch JP, editor. Lung biology in health and disease; 2006. p. 1–16.Google Scholar
  2. 2.
    Yusen RD, Edwards LB, Kucherayavaya AY, Benden C, Dipchand AI, Goldfarb SB, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-second official adult lung and heart-lung transplantation report--2015; focus theme: early graft failure. J Heart Lung Transplant. 2015;34(10):1264–77.CrossRefPubMedGoogle Scholar
  3. 3.
    Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014 – an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34:1):1–15.CrossRefPubMedGoogle Scholar
  4. 4.
    Judge EP, Foweraker JE, Lordan JL. Infectious disease issues pertinent to cystic fibrosis patients in the pre-lung transplantation period. In: Mooney ML, Hannan MM, Husain S, Kirklin JK, editors. ISHLT monograph 5: diagnosis and management of infectious diseases in cardio-thoracic transplantation and mechanical circulatory support. Addison: International Society of Heart and Lung Transplantation; 2011.Google Scholar
  5. 5.
    Lobo LJ, Noone PG. Respiratory infections in patients with cystic fibrosis undergoing lung transplantation. Lancet Respir Med. 2014;2(1):73–82.CrossRefPubMedGoogle Scholar
  6. 6.
    Yates B, Murphy DM, Fisher AJ, Gould FK, Lordan JL, Dark JH, et al. Pseudomembranous colitis in four patients with cystic fibrosis following lung transplantation. BMJ Case Rep. 2009;2009. pii: bcr11.2008.1218.
  7. 7.
    Lordan JL, Corris PA. Pulmonary arterial hypertension and lung transplantation. Expert Rev Respir Med. 2011;5(3):441–54.CrossRefPubMedGoogle Scholar
  8. 8.
    Cypel M, Yeung JC, Liu M, Anraku CF, Karolak W, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med. 2011;364(15):1431–40.CrossRefPubMedGoogle Scholar
  9. 9.
    de Perrot M, Granton JT, McRae K, Cypel M, Pierre A, Waddell TK, et al. Impact of extracorporeal life support on outcome in patients with idiopathic pulmonary arterial hypertension awaiting lung transplantation. J Heart Lung Transplant. 2011;30(9):997–1002.CrossRefPubMedGoogle Scholar
  10. 10.
    Fuehner T, Kuehn C, Hadem J, Wiesner O, Gottlieb J, Tudorache I, et al. Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation. Am J Respir Crit Care Med. 2012;185(7):763–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Fischer S, Simon AR, Welte T, Hoeper MM, Tessman R, Meyer A, et al. Bridge to lung transplantation with the novel pumpless interventional lung assist device NovaLung. J Thorac Cardiovasc Surg. 2006;131(3):719–23.CrossRefPubMedGoogle Scholar
  12. 12.
    Hartert M, Senbaklavacin O, Gohrbandt B, Fischer BM, Buhl R, Vahld CF. Lung transplantation: a treatment option in end-stage lung disease. Dtsch Arztebl Int. 2014;111(7):107–16.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Aigner C. Lobar lung transplantation: more than bits and pieces. Eur J Cardiothorac Surg. 2014;45(2):370–1.CrossRefPubMedGoogle Scholar
  14. 14.
    Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D, et al. Report of the ISHLT Working Group on primary lung graft dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2005;24(10):1454–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Remund KF, Best M, Egan JJ. Infections relevant to lung transplantation. Proc Am Thorac Soc. 2009;6(1):94–100.CrossRefPubMedGoogle Scholar
  16. 16.
    Husain S, Sole A, Alexander BD, Aslam S, Avery R, Benden C, et al. The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: executive summary. J Heart Lung Transplant. 2016;35(3):261–82.CrossRefPubMedGoogle Scholar
  17. 17.
    McDonnell M, Lordan J. Review of immunosuppressive treatment in lung transplantation. Turk Thorac J. 2014;15:94–101.CrossRefGoogle Scholar
  18. 18.
    Vanaudenaerde BM, Meyts I, Vos R, Geudens N, De Wever W, Verbeken EK, et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J. 2008;32(4):832–43.CrossRefPubMedGoogle Scholar
  19. 19.
    Suwara M, Vanaudenaerde BM, Verleden SE, Vos R, Green NJ, Ward C. Mechanistic differences between phenotypes of chronic lung allograft dysfunction after lung transplantation. Transpl Int. 2014;27(8):857–67.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Corris PA, Ryan VA, Small T, Lordan J, Fisher AJ, Meachery G, et al. A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation. Thorax. 2015;70(5):442–50.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Robertson AG, Ward C, Pearson JP, Smart T, Lordan J, Fisher AJ, et al. Longitudinal changes in gastro-oesophageal reflux from 3 months to 6 months after lung transplantation. Thorax. 2009;64(11):1005–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Botha P, Archer L, Anderson RL, Lordan J, Dark JH, Corris PA, et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation. 2008;85(5):771–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Cardiothoracic Block/Institute of TransplantationFreeman HospitalNewcastle upon TyneUK

Personalised recommendations